Cargando…
M403 COVID-19 IN A PATIENT WITH HYPER-EOSINOPHILIC SYNDROME TREATED WITH MEPOLIZUMAB
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661915/ http://dx.doi.org/10.1016/j.anai.2020.08.350 |
| _version_ | 1783609296679862272 |
|---|---|
| author | Khakwani, Z. Kumar, S. |
| author_facet | Khakwani, Z. Kumar, S. |
| author_sort | Khakwani, Z. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7661915 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Published by Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-76619152020-11-13 M403 COVID-19 IN A PATIENT WITH HYPER-EOSINOPHILIC SYNDROME TREATED WITH MEPOLIZUMAB Khakwani, Z. Kumar, S. Ann Allergy Asthma Immunol Article Published by Elsevier Inc. 2020-11 2020-11-13 /pmc/articles/PMC7661915/ http://dx.doi.org/10.1016/j.anai.2020.08.350 Text en Copyright © 2020 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Khakwani, Z. Kumar, S. M403 COVID-19 IN A PATIENT WITH HYPER-EOSINOPHILIC SYNDROME TREATED WITH MEPOLIZUMAB |
| title | M403 COVID-19 IN A PATIENT WITH HYPER-EOSINOPHILIC SYNDROME TREATED WITH MEPOLIZUMAB |
| title_full | M403 COVID-19 IN A PATIENT WITH HYPER-EOSINOPHILIC SYNDROME TREATED WITH MEPOLIZUMAB |
| title_fullStr | M403 COVID-19 IN A PATIENT WITH HYPER-EOSINOPHILIC SYNDROME TREATED WITH MEPOLIZUMAB |
| title_full_unstemmed | M403 COVID-19 IN A PATIENT WITH HYPER-EOSINOPHILIC SYNDROME TREATED WITH MEPOLIZUMAB |
| title_short | M403 COVID-19 IN A PATIENT WITH HYPER-EOSINOPHILIC SYNDROME TREATED WITH MEPOLIZUMAB |
| title_sort | m403 covid-19 in a patient with hyper-eosinophilic syndrome treated with mepolizumab |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661915/ http://dx.doi.org/10.1016/j.anai.2020.08.350 |
| work_keys_str_mv | AT khakwaniz m403covid19inapatientwithhypereosinophilicsyndrometreatedwithmepolizumab AT kumars m403covid19inapatientwithhypereosinophilicsyndrometreatedwithmepolizumab |